An NCI-designated Consortium Cancer Center
|
|
|
Weekly Research Newsletter
|
Week of February 27, 2023
|
|
|
Now Recruiting: Moores Cancer Center (MCC) Clinical Trials Office (CTO) co-Medical Directors
MCC and CTO are now seeking candidates for the position of MCC CTO co-Medical Directors. MCC and CTO have expanded the support for the role to now recruit two faculty leaders to provide oversight of cancer clinical trials. The leadership responsibilities will be shared equally by the two co-Medical Directors; however, each will possess a different portfolio of duties and shared oversight at MCC and all locations where MCC clinical trials are conducted.
The principal role of the CTO co-Medical Directors is to direct overall CTO clinical strategies and operations to ensure safe, compliant, and efficient cancer clinical trial conduct. The co-Medical Directors will report to the MCC Associate Director for Clinical Science and receive strategic guidance from the not only the MCC executive team, but also Health Sciences leadership.
Any interested faculty members are encouraged to submit (1) a letter of interest that includes your vision for the position and (2) a recent CV to Xochitl Villanueva at xvillanueva@health.ucsd.edu by Monday, March 13, 2023.
|
|
|
MCC Cancer Services Town Hall
At the first MCC Quarterly Town Hall on February 13, 2023, the MCC draft strategic plan, MCC clinical volume and finance updates, and MCC Research Administration progress on delivering the best “researcher experience” possible were presented. This hybrid event, held in MCC Goldberg Auditorium and on Zoom, was attended by 300 participants. In the event that you missed it, below is the link and password to the recording of the presentations and Q&A segments.
https://uchealth.zoom.us/rec/share/myGjAaUhb6JmWD7xEXspVq53ItLt4vNqB5TrL6bPFGKHnFrSxI2h6la4itfUoA.dRK3OL9r1btXWo0s
Passcode: Townhall4!
Link expires March 14, 2023.
|
|
|
OncLive State of the Science Summit: Breast Cancer
Thursday, March 9, 2023 from 6:00 p.m. to 9:00 p.m.
Hilton San Diego / Del Mar
15575 Jimmy Durante Boulevard
Del Mar, CA 92014
Chaired by Jennifer M. Matro, M.D.
|
|
|
Now Recruiting: MCC Providers for UC San Diego Health: Sanford Compassionate Communication Academy Fellowship
The Center for Compassionate Communication, housed within the Sanford Institute for Empathy and Compassion, is currently recruiting fellows for the UC San Diego Health: Sanford Compassionate Communication Academy Fellowship, which encourages the application of arts and humanities lessons to medical communication training, with the goal of improving connections not only between physicians and patients, but also among healthcare teams.
The fellowship program offers 60 hours of training (a mix of virtual, synchronous, and in-person sessions) over 6 months, beginning in June 2023. UC San Diego physicians, APPs, RNs and medical educators are eligible to apply for the fellowship and will receive a $7,500 stipend to participate, if accepted. For more information, click here. To apply for the fellowship by March 6, 2023, click here.
|
|
|
Join the MCC Work in Progress Seminar Series
Please join MCC's standing Work in Progress Seminar Series every first Wednesday of the month. If you are interested in presenting or joining, then please contact Program Coordinator, Diana Arroyo at d1arroyo@health.ucsd.edu.
|
|
|
Highlights from The Cancer Letter |
ODAC Gives Thumbs-up to GSK Plan to Build on MSK Rectal Cancer Study of Dostarlimab that Produced 100% Response
Read full article on page 5 of The Cancer Letter, volume 49 number 7.
Biden Places Cancer in Top Spot on Unity Agenda; Announces New Moonshot Programs
Read full article on page 28 of The Cancer Letter, volume 49 number 7.
|
|
|
|
Pharmacology Seminar Series
Structural and Mechanistic Insights into the Regulation and Pharmacology of the Ras/Raf/MAP Kinase Pathway
Tuesday, February 28, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
UC San Diego, School of Medicine
Optional Webinar Registration
Michael J. Eck, M.D., Ph.D.
Professor of Cancer Biology
Dana-Farber Cancer Institute
Professor of Biological Chemistry and Molecular Pharmacology Harvard Medical School
Hosted by Roger Sunahara, Ph.D.
|
|
|
|
Cancer Control Program Work In Progress Seminar Series
Integrating “When to Eat” and “Who Should Eat” and Concepts to Evaluate Inflammatory Foods
Wednesday, March 1, 2023 at 12:00 p.m. PT
MCC Comor Commons Conference Room
Lunch provided, beginning at 11:30 a.m.
Optional Webinar Registration
Tianying Wu, Ph.D.
Associate Professor
San Diego State University, School of Public Health
Division of Epidemiology and Biostatistics
|
|
|
|
Pharmacology Seminar Series
The Fibroblastic Cell/ECM Functional Unit in Healthy and Cancer-perturbed Organs
Wednesday, March 7, 2023 at 12:00 p.m. PT
Leichtag Biomedical Research Building, Room 107
UC San Diego, School of Medicine
Optional Webinar Registration
Edna Cukierman, Ph.D.
Professor, Institute for Cancer Research
Co-Leader, Cancer Signaling and Epigenetics Program
Co-Director, Marvin and Concetta Greenberg Pancreatic Cancer Institute
Co-Director, Immune Monitoring Facility
Fox Chase Cancer Center, Temple Health Philadelphia
|
|
|
COMMUNITY OUTREACH AND ENGAGEMENT
|
|
|
Make San Diego HPV Cancer Free
Monday, February 27, 2023 from 10:00 a.m. to 11:30 a.m. PT
Between 2020 and 2022, approximately 120,000 fewer children aged 11 to 13 years in in California began their HPV vaccine series, compared to pre-pandemic levels in 2019, according to the California Immunization Registry. Getting these California children caught up on cancer prevention is extremely important.
Please join SD PATH, a workgroup of MCC, for its 3rd annual, Make SD HPV Cancer Free Summit on February 27, 2023. This meeting will address the following:
|
- Local and state HPV vaccination rates
- The case for age 9 HPV vaccination promotion
-
SD PATH partnership spotlights: Success stories and future promise of HPV
- Vaccination interventions in San Diego County
|
| |
Student Volunteers Available
MCC Cancer Research, Training, Education, and Coordination (CRTEC) has identified three motivated undergraduate students who are interested in volunteering in a lab at MCC. This is a win-win research experience for the students and your lab. Please contact Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu, if you would like to connect with one or more of these students:
|
- Third-year UCSD undergraduate majoring in Biology, minoring in Math
- Second-year UCSD premed undergraduate majoring in Human Biology
-
First-year UCSD undergraduate majoring in Cognitive and Behavioral Neuroscience
|
CRTEC administration will complete all necessary paperwork for these student volunteers.
|
|
|
Speed Mentoring Workshop, Faculty Sign Ups
Faculty Members of MCC are invited to serve a mentors at the MCC Speed Mentoring Workshops, organized by MCC CRTEC. These workshops serve not only undergraduate, graduate, and post-graduate students, but also project scientists, research scientists, and junior faculty. Please select the session(s) for which are are available to mentor, and please select all that apply. You will be scheduled for only one of the dates that you choose—providing several dates merely helps to coordinate schedules. You will be contacted with a confirmation of the schedule.
CRTEC Speed Mentoring takes place on the second Thursday of each month from 12:00 p.m. to 1:00 p.m. on Zoom. Participating faculty members will receive 1 hour of mentorship credit, approved by MCC leadership.
|
|
|
HIGHLIGHTED FUNDING OPPORTUNITIES
|
|
|
Tina’s Wish, Rising Star Grant Opportunity: 2024–2025
The Honorable Tina Brozman Foundation (Tina’s Wish) is releasing the RFP for its Rising Star Grants, 2024-2025. To plan appropriately, Tina's Wish requires that all those interested in applying for this grant take 30 seconds to submit a Rising Star Grant Intent to Apply form. Click here to learn more about Tina’s Wish.
Grant Objective
Tina’s Wish is committed to supporting early career researchers who bring fresh approaches to the study of the early detection or prevention of ovarian cancer. The grant assists and supports promising researchers in the ovarian cancer field and encourages them to take risks and develop innovative projects.
Please note that Rising Star Grants are separate and distinct from Tina's Wish, Team Science Grants. The Rising Star Grant is funded at $75,000/year for 2 years; the total grant award is $150,000.
Please click here to access the Intent to Apply form, which applicants must complete by Wednesday, March 1, 2023 by 12:00 p.m. ET to receive a link to submit a full proposal. The full RFP will be sent once the Intent to Apply form has been submitted. Full proposals will be due on or before Monday, April 17, 2023 at 12:00 p.m. ET.
Eligibility and Selection Criteria (applicants must meet ALL criteria)
|
- Applicants must be working in either a school of medicine or public health or a recognized non-profit scientific research facility in the United States.
-
Applicants must have a committed mentor to support him/her throughout the grant period. The mentor does not need to be at the same institution as the applicant, provided that the mentor is committed to a meaningful and productive mentorship relationship throughout the grant period.
-
If a current mentor is not connected to the ovarian cancer research community, then secure a mentor who is a subject matter expert in the ovarian cancer field. If assistance is needed in securing such a mentor, then contact Tina’s Wish (this will not reflect negatively on any proposal).
- The research project for which support is requested should be innovative and not currently funded.
-
Applicants should hold a Ph.D., M.D., or M.D., Ph.D. degree.
-
Ph.D. applicants must be within 3 years of completing their degree and be at the postdoctoral level of training or similar (a non-tenured level position) when the grant begins in January, 2024. If one is at the Instructor level, one is eligible to apply for this grant if one’s lab is embedded in a more senior/established lab; if at the Instructor level and as an independent lab, please review the Team Science Grant opportunity).
-
M.D. or M.D., Ph.D. applicants must be at the instructor or assistant professor level (or a similar faculty position) and within 3 years of starting their first faculty appointment at the time of the estimated award date (January, 2024). Clinical or research fellows with dedicated research time for the two years of the Rising Star Grant funding period (January 2024-December 2025) also will be eligible. Fellows should include a letter of institutional commitment of at least 75% research time for the Rising Star Grant funding period with their application.
- Prevention studies should target early cancer interception and include chemoprevention strategies.
|
Deadline: Wednesday, March 1, 2023
|
| |
V Foundation 2023 Call for Adult Translational Cancer Research Focus Area: Therapeutic Resistance
MCC is pleased to announce the V Foundation 2023 Call for Adult Translational Cancer Research. This limited submission request is specifically for adult cancer research through the Translational grant mechanism. Applicants may propose adult cancer research that either moves a novel strategy from the laboratory into a human clinical trial or uses specimens from a clinical trial to develop biomarkers or mechanisms. The proposed research should apply in some direct way to human beings within less than 3 years from the end of the grant. If biomarker research is undertaken, then a validation set or independent clinical trial is essential. A plan for biomarker validation, if applicable, must be included in any proposal. The endpoint of the project should be the planning or initiation of a new clinical trial.
This RFA is specifically for adult cancer research that falls into preclinical/translational practice, as described above. In addition, this year, V Foundation has a special interest in and funding for therapeutic resistance; therefore, proposed research projects in this area are welcome. Please note that areas not included in this scope are epidemiology, behavioral science, and health services research. This is an $800,000 grant, paid in four annual installments.
MCC can nominate only candidate for this call. To be considered for nomination, please send a 1-page Letter of Intent (LOI) to Divya Subramonian, Ph.D. at dsubramonian@health.ucsd.edu for review by the MCC grants committee. LOI instructions are listed below; the RFA is attached.
All LOIs must be submitted to Divya Subramonian, Ph.D. at dsubramonian@health.ucsd.edu as a single PDF by the internal deadline of Monday, March 6, 2023 at 5:00 p.m. Please follow the instructions below:
|
- Letter of Intent/Research Statement (1 page maximum)
- Arial, at least 11-point font, at least 1/2-inch margins, 1 page maximum, including any figures or tables; citations only may be included on a second page.
-
Include your name, degree(s), title, department, phone number, email address, statement of your eligibility per V Foundation guidelines, and project title.
- Briefly describe the nature of the research project, including a brief summary of aims, significance and rationale, preliminary data, and the research plan.
- NIH-style bio sketch
-
5 pages maximium; include active and pending support.
- Your LOI submission is NOT complete until you have received Acknowledgment of Receipt.
|
Deadline: Monday, March 6, 2023
|
|
|
SITC Fellowships: Funding Opportunities for Early Career Scientists
The Society for Immunotherapy of Cancer (SITC) is committed to assisting young investigators in advancing the science of immunotherapy. This year, the SITC Forward Fund is pleased to offer four SITC Fellowships, totaling $440,000 in funding. Get started on your application now! Submissions are due by March 27, 2023.
SITC Fellowships are only available to SITC members. Not a member? Sign up today.
Deadline: Monday, March 27, 2023
|
|
|
University of California, Hematologic Malignancies Consortium (UCHMC) Request for Proposals (RFP)
The UCHMC is requesting submission of proposals within two potential areas of funding: RFP A and RFP B.
All applications are to be submitted via email as a single PDF to Jesika Reiner, M.P.H., M.B.A. at JReiner@uchmc.org and Mwieduwilt@uchmc.org.
RFP A: UCHMC Funds for Junior Faculty and Trainee Competitive Seed Grants
This funding will support single or multi-center pilot clinical trials, translational lab-based projects, or retrospective projects, which may ultimately grow into multi-center UCHMC interventional clinical trials. Funding may be applied for fellowship support to conduct clinical trials research with the UCHMC. Funding also may support correlative research that may or may not be associated with an existing UCHMC trial yet with translational aims that possess potential for development into a UCHMC trial. The award amount will be determined by the UCHMC Steering Committee, but individual requests should not exceed $40,000.
RFP B: UCHMC Funds for Clinical Trials Support
This funding will support underfunded yet promising clinical trials and correlative research projects associated with an existing clinical trials or other multi-center projects that hold promise for development into larger multicenter UCHMC clinical trials. These awards will range from $100,000 to $150,000 in a given award period, with the number of projects awarded based on number of applications and scientific need as determined by the UCHMC Steering Committee, which reserves the right to award a larger total funds as it see fit.
Applicants may apply for both RFPs but will be awarded only one as a lead investigator. An applicant can be a collaborator on more than one application in a given award period.
Application Format
|
- Cover Page
- Project title
- Project investigators (Lead and Sub-Investigators) and affiliations
- Project start date
- Project end date
- Concurrent UCHMC applications of Lead Investigator
- Applicant contact
- Project Information
- Brief project description with hypothesis(es)
- Detailed project description with supporting preclinical and/or clinical data, rationale, study design, and statistical plan, as appropriate
- Budget
- Budget justification
- Other sources of funding
-
Statement of commitment to develop results into UCHMC interventional clinical trials when possible
- Attachments
- CVs of investigators associated with the proposed project
|
|
|
Call for Applications to Fund Travel to Scholarly Meeting for FY 2022-2023, Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
Applications may be submitted throughout the year but must be received and approved prior to the conference start date. Applications will be reviewed while funds are available. Funds will not be awarded retroactively.
Any UCSD Health Sciences (HS) Clinical series faculty member holding an M.D. or D.O. can receive one trip every other fiscal year (July 1-June 30). Travel awards (domestic or foreign) will be made for a maximum of $750 toward standard economy airfare and/or registration fees (documentation required).
Eligibility is to HS Clinical series faculty who (1) have an accepted abstract to a scientific professional society conference, (2) are not a member of the Academic Senate, and (3) are either the first or senior author on the abstract podium or poster presentation of original clinical research. Invited lectures, workshops, or panel or moderator invites are ineligible and will not be considered.
|
|
|
Co-infection and Cancer (R01 and R21 Clinical Trial Not Allowed)
R01 Award: Maximum duration is 5 years. For over $500,000/year in direct costs, NIH approval is required.
R21 Award: Combined budget for direct costs for the 2-year maximum project period may not exceed $275,000. No more than $200,000 may be requested in any single year.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
NCI Program Project Applications for 2023, 2024, and 2025 (P01 Clinical Trial Optional)
Award: Application budgets are not limited yet must reflect the actual needs of the proposed project. The project period may not exceed 5 years.
The purpose of this FOA is to enhance mechanistic and epidemiologic investigations that address the roles of co-infection and cancer to illuminate presently unestablished pathways in carcinogenesis that may inform prevention and treatment strategies for infection-related cancers. Co-infection is defined as the occurrence of infections by two or more infectious (pathogenic or non-pathogenic) agents—either concurrently or sequentially—and includes both acute and chronic infections by viruses, bacteria, parasites, and/or other microorganisms. Preference will be given to investigations of co-infections with known oncogenic agents (excluding human immunodeficiency virus [HIV]) and co-infections that engender novel opportunities for prevention and treatment.
Deadline: NIH standard submission dates apply.
|
|
|
DoD Fiscal Year 2023 (FY23) Breast Cancer Research Program (BCRP) and Peer Reviewed Medical Research Program (PRMRP) Funding Opportunities
BCRP Awards
|
- Breast Cancer Research Program
- Transformative Breast Cancer Consortium Award
- **NEW for FY23** Transformative Breast Cancer Consortium Development Award
- Clinical Research Extension Award
- Breakthrough Award Level 1 and Level 2
- Breakthrough Award Level 3
- Breakthrough Award Level 4
- Era of Hope Scholar Award
- Innovator Award
|
- Clinical Trial Award
- Discovery Award
- Focused Program Award
- Investigator-Initiated Research Award
- Lifestyle and Behavioral Health Interventions Research Award
- Technology/Therapeutic Development Award
|
A pre-application is required and must be submitted through the electronic Biomedical Research Application Portal (eBRAP) at https://eBRAP.org prior to the pre-application deadline. All applications must conform to the final Funding Opportunities/Program Announcements and General Application Instructions, which can be found on the Grants.gov website (https://Grants.gov).
|
|
|
OTHER FUNDING OPPORTUNITIES
|
|
|
2023 AIM-HI Women's Venture Competition
The AIM-HI Women's Venture Competition, now in its fourth year, is open to women-led oncology companies worldwide. The program provides lifeline seed funding, critical coaching, and continuous access to AIM-HI's valuable global network to address unmet medical needs for cancer patients.
Benefits include unique opportunities for women-led oncology companies to (1) apply for up to $1 million investment, (2) receive recognition, visibility, and introductions to cancer experts worldwide, and (3) be featured in the Award Ceremony for the 2023 Women's Venture Competition and network with key opinion leaders, business executives, investors, and fellow women entrepreneurs in the life science startup ecosystem.
Deadline: Wednesday, March 15, 2023
|
|
|
Notice of Special Interest (NOSI): Research on the Etiology, Early Detection, Screening and Prevention of Early-Onset Colorectal Cancer
This NOSI applies to due dates on or after January 5, 2023 and subsequent receipt dates through July 2, 2025. You may submit applications for this initiative using any of the 30 FOAs listed on the website below or any reissues of these announcement through the expiration date of this notice.
The purpose of this NOSI is to solicit applications directed toward (1) identifying, characterizing, and mitigating risk factors and (2) identifying biomarkers for early detection, best screening modalities, and preventive interventions for early-onset colorectal cancer (EOCRC), defined as occurring before 50 years of age.
|
|
|
NOSI: Administrative Supplement to Support Global Cancer Stigma Research
Through this NOSI, the NCI is providing an opportunity for supplemental funding to support exploratory research studies to expand the current understanding of cancer stigma (as defined below), assess its impact on cancer control and prevention, and develop stigma-reduction interventions to improve cancer outcomes in low- and middle-income countries (LMICs).
Applications can be submitted on a rolling basis between January 16, 2023 and May 21, 2023 at 5:00 p.m. local time of applicant organization for FY 2023 funding. Applications for this initiative must be submitted using the following FOA or its subsequent reissued equivalent: PA-20-272
|
|
|
NOSI: Career Development Opportunities for Research within the Mission of the Division of Cancer Prevention (DCP) at the National Cancer Institute (NCI)
This NOSI applies to due dates on or after February 12, 2023, and subsequent receipt dates through November 13, 2024. You may submit applications for this initiative using any of the fifteen funding opportunity announcements (FOAs) listed on the website below, or any reissues of these announcement through the expiration date of this notice.
Through this NOSI, the NCI hopes to continue receiving Career Development Award applications from early career scientists conducting research within the mission of the DCP.
Priority research areas for DCP include but are not limited to the following:
|
- Cancer Prevention and/or Interception
- Cancer Early Detection and/or Screening
- Symptom Science
|
|
|
NOSI: Technology Development for Cancer Control and Population Science Research.
This NOSI applies to due dates on or after March 1, 2023 and subsequent receipt dates through the expiration date of this notice.
The purpose of this NOSI is to encourage grant applications for the development of novel technologies to support the needs of cancer control and population sciences research including healthcare delivery research, surveillance research, behavioral research, cancer epidemiology, and population-scale omics research, with the goal of driving innovation in this field.
|
|
|
NOSI: Administrative Supplement for NCI Cancer Prevention-Interception Targeted Agent Discovery Program (CAP-IT)
One CAP-IT Data and Resource Coordination Center will be awarded with a maximum total cost of $800,000 per year (maximum direct cost is $480,000 per year) in fiscal year 2023; at least 1 full year on the parent grant must remain at the time of funding; application budget is limited to 4 years.
Deadline: February 28, 2023
|
| RFA: Aging & Cancer Research with the Mark Foundation
Awards will provide $500,000 total over 3 years ($250,000 to each PI).
Deadline: March 1, 2023 at 5:00 p.m.
|
| RFA: Aging & Cancer Research with the Israel Cancer Research Fund
Two collaborative projects will be funded; each project will be awarded $200,000 per year for 2 years, or a total of $400,000, with each research group receiving $100,000 per year ($200,000 total); successful projects may be eligible for a third year of funding at the level of $100,000 ($50,000 per research group).
LOI Deadline: March 1, 2023 at 5:00 p.m.
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| DOD Ovarian Cancer, Investigator-Initiated Research Award
Amounts from $300K to $800K; pre-application required; due dates April 17 2023.
Deadline: July 21, 2023
|
| DOD Lung Cancer, Translational Research Award
Amounts from $375K to $1.2M; pre-application required; due dates May 2 and May 10 2023.
Deadline: August 3, 2023
|
|
|
Revision Applications for Incorporation of Novel NCI-Supported Technology to Accelerate Cancer Research (U01, P01, R01, U2C Clinical Trial Optional)
Application budgets may not exceed $150,000 in direct costs per year.
Deadline: March 1, 2023 and September 1, 2023
|
| NCI Small Grants Program for Cancer Research for Years 2023, 2024, and 2025 (NCI Omnibus) (R03 Clinical Trial Optional)
A budget for direct costs of up to $50,000 per year may be requested; maximum project period is 2 years.
Deadline: Standard NIH deadlines apply
|
|
Development of Innovative Informatics Methods and Algorithms for Cancer Research and Management (R21 Clinical Trial Optional)
The combined budget for direct costs for the 2-year maximum project period may not exceed $275,000; no more than $200,000 may be requested in any single year.
Deadline: Standard NIH deadlines apply
|
|
|
Sustained Support for Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Application budgets are not limited but must reflect the actual needs of the proposed project; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| Advanced Development of Informatics Technologies for Cancer Research and Management (U24 Clinical Trial Optional)
Budgets are limited to $600,000 direct costs (excluding consortium F&A) per year; maximum project period is 5 years.
Deadline: Standard NIH deadlines apply
|
| NOSI: Adaptive Biomaterials for Cancer Biology
This NOSI invites applications that propose the development of advanced biomaterials for use in fundamental cancer biology research and proposals incorporating the novel application of advanced biomaterials to address cancer biology research questions.
Deadline: Standard NIH deadlines apply
|
|
|
POSTDOCTORAL FUNDING OPPORTUNITIES
|
|
|
MCC Cancer Therapeutics Training (CT2) Program: Open Positions Available
PIs: Dr. Michael Bouvet and Dr. Dwayne Stupack
Description: The goal of the CT2 Program is to train the next generation of leaders in the field of cancer drug and diagnostics development. The CT2 Program is open to both M.D.s and Ph.D.s and provides an intensive 2-year period of research and training in the development of novel cancer therapeutics or diagnostics at MCC. Trainees not only execute a research program under the direction of a member of the faculty of this NCI-Designated Comprehensive Cancer Center, but also participate in coursework, seminars, and lectures. The research may be basic, translational, or clinical, yet all trainees will become versed in each major phase of the drug development process. Graduates of the program are prepared to transition to leadership roles in cancer therapeutics development in either an academic or commercial environment.
Salary/Stipend Information: NIH stipend scale
Application Procedure, Documents, and Requirements
See website for more details about CT2 program: WEBSITE
|
- Complete CT2 program application (form available to download from the website above)
- Curriculum vitae
- One-page personal statement
- Proof of U.S. citizenship or permanent resident status
- Three letters of recommendation (one from an identified mentor)
- Ph.D. or M.D. degree
|
For more information or to apply, please contact
Amy Spilkin, Ph.D. at aspilkin@health.ucsd.edu
Deadline: March 15, 2022
|
| |
American Association for the Study of Liver Diseases (AASLD), Harold Amos Medical Faculty Development Program (AMFDP) Award Opportunity
Applications available: February 8, 2023
Application deadline: March 16, 2023
As part of AASLD's efforts to advance our shared goal of cultivating the next generation of academic leaders, AASLD has partnered with the AMFDP of the Robert Wood Johnson Foundation (RWJF). The program has been designed to increase the number of scholars from historically marginalized groups in the field of hepatology with academic and research appointments. The AASLD-AMFDP Award offers 4 years of postdoctoral research support to historically disadvantaged physicians who are committed to developing careers in academic medicine and serving as role models for students and faculty of similar backgrounds.
About the AASLD-AMFDP (Harold Amos Award)
For over 20 years, RWJF has worked to increase the representation of minority scholars in academic medicine through its AMFDP, which was created to assist faculty from historically disadvantaged backgrounds to achieve senior rank in academic medicine. The AMFDP is named after Harold Amos, Ph.D., who was the first African-American to chair a department (now the Department of Microbiology and Medical Genetics) at Harvard Medical School.
The AASLD Governing Board recently approved support for the program to strengthen its commitment to diversity, equity, and inclusion efforts in hepatology. Through the program, AASLD is committed to funding one AMFDP hepatology scholar for 4 years. The selected scholar (1) is expected to spend at least 70 percent of his or her time on research activities, in association with a senior faculty member located at an academic medical center and (2) will receive an annual stipend of up to $75,000, complemented by a $30,000 annual grant toward support of research activities.
Program Mentorship
The selected awardee will be assigned a National Advisory Committee mentor, following an application review and an in-person interview, who will follow his or her progress throughout the award term and provide additional guidance.
The selected cohort will meet for mentoring and leadership training.
Eligibility Requirements
To be eligible for this award, the applicant must meet the following requirements:
|
-
Physician or nurse from a historically disadvantaged background (ethnic, financial, or educational) who has excelled in his or her education
- U.S. citizen or permanent resident at the time of the application deadline
- Completing or have completed formal clinical training
- Prepared to devote 4 consecutive years to research
-
Committed to pursuing an academic career and improving the health status of the underserved, decreasing health disparities, or serving as a role model for students and faculty from historically disadvantaged backgrounds.
|
Application Process
To view detailed application requirements and begin the application process, please visit the AMFDP website.
|
|
|
Kyoto University Symposium
Tuesday, February 28, 2023 from 1:00 p.m. to 5:00 p.m.
Roth Auditorium
Sanford Consortium for Regenerative Medicine
|
|
|
| Keynote Speaker
Dr. Shinya Yamanaka
Nobel Laureate in Physiology or Medicine 2012
Director Emeritus and Professor
Department of Life Science Frontiers
Center for iPS Cell Research and Application
Kyoto University
Read More
|
|
|
The symposium will be followed by a reception at the Bella Vista Cafe. Save the date and join us for this unique opportunity to reinvigorate academic collaborations with the prestigious university in Japan.
For more information, please contact Ms. Mariko Adachi, International Strategy Office, Kyoto University at osl.symposium@mail2.adm.kyoto-u.ac.jp
|
|
|
Solid Tumor Therapeutics Program Retreat
Friday, March 3, 2023 from 9:00 a.m. to 4:30 p.m.
MCC Goldberg Auditorium
The retreat will include catered breakfast and lunch.
|
|
|
Luis Diaz, M.D.
Grayer Family Chair Head, Division of Solid Tumor Oncology Professor, Weill Cornell Medical School
|
|
Lisa Butterfield, Ph.D.
Adjunct Professor of Microbiology and Immunology
University of California, San Francisco
|
|
|
Additional Speakers Include
Sonia Sharma, Ph.D. Anandra W. Goldrath, Ph.D. Liangfang Zhang, Ph.D. Nicole Steinmetz, Ph.D. Shweta Joshi, Ph.D. Tariq Rana, Ph.D. Rebekah White, M.D., FACS Rebecca Shatsky, M.D.
|
|
|
OncLive State of the Science Summit: Breast Cancer
Thursday, March 9, 2023 from 6:00 p.m. to 9:00 p.m.
Hilton San Diego / Del Mar
15575 Jimmy Durante Boulevard
Del Mar, CA 92014
Chaired by Jennifer M. Matro, M.D.
|
|
|
SITC Advances in Cancer Immunotherapy: A Focus on Lung Cancers
Thursday, April 6, 2023 from 12:00 p.m. to 4:00 p.m.
San Diego and Virtual
Free for healthcare professionals, students, patients, and patient advocates, this Advances in Cancer Immunotherapy program is CME-, CNE-, CPE- and MOC-certified and will be presented by leading authorities in tumor immunology and cancer immunotherapy. The program will provide the latest updates in immunotherapy for lung cancers and address practical applications, immune-related adverse events, and future trends.
|
|
|
Structural and Functional Genomics Program Retreat
Friday, May 5, 2023
MCC Goldberg Auditorium and Lobby
The retreat will include breakfast and lunch.
|
|
|
Joseph Califano, M.D.
Director, MCC
Director, Gleiberman Head & Neck Cancer Center
Professor, Department of Otolaryngology/Head & Neck Surgery, UCSD, School of Medicine
Co-Leader, MCC, Structural and Functional Genomics Program
|
| Jill P. Mesirov, Ph.D.
Associate Vice Chancellor for Computational Health Sciences Professor, Department of Medicine, UCSD School of Medicine
Co-Leader, MCC, Structural and Functional Genomics Program
|
|
|
Big Data Training for Cancer Research—BigCare 2023 Summer Workshop
Friday, May 19, 2023 to Sunday, May 28, 2023
Purdue University
West Lafayette, Indiana
There is no cost for registration or tuition for this workshop, which will be held on-site at Purdue University. Moreover, there will be no cost for food or lodging, and travel scholarships will be available for a limited number of participants. Please visit the Purdue University Website for updates.
|
|
|
SHARED RESOURCE SPOTLIGHT
|
|
|
MCC Biobehavioral Shared Resource (BBSR)
The goal of the BBSR is to enhance the feasibility and success of MCC investigators studying not only lifestyle behaviors and effect of interventions, but also biological indicators of cancer outcome, to reduce cancer risk and increase survival following the diagnosis of cancer. The BBSR provides expertise and guidance in developing and operationalizing behavioral research for MCC members who either do not have expertise in these areas or who have limited resources to use high-quality, science-based methodology without the context and efficiency of a consolidated service core.
The BBSR provides the following services:
|
-
Biological indicators assessment, which includes development of biological specimen processing protocols plus direct services for sample collection (e.g., phlebotomy) and processing (e.g., DNA and RNA extraction and small scale genotyping), instrument use (e.g., QiaCube), and laboratory analysis conducted in-house or by outside laboratories.
-
Behavioral assessment (e.g., dietary intake, physical activity, and body composition), which includes protocol development plus direct services (e.g., providing devices and training, conducting dietary recalls and questionnaires, and processing data).
-
Behavioral intervention services, which include guidance on design and content for weight loss, diet and physical activity interventions, protocol development, training, and guidance with new communication modalities.
|
The BBSR collaborates with the UCSD Exercise and Physical Activity Resource Center (EPARC), which facilitates the use of subsidized, accessible services relating to physical activity, fitness, strength, and body composition.
BBSR laboratory instrumentation and methodologies enable analysis of nutrients and dietary biomarkers in biological samples that are not generally available through clinical laboratories. Biological samples may include blood, urine, saliva, cell culture media, products, and formulations.
The BBSR not only provides services to members of other NCI-Designated Comprehensive Cancer Centers, but also supports clinical research projects conducted by NCI-supported cooperative groups.
Contact BBSR for More Information
For laboratory biological indicators assessment and sample collection, email Brinda Rana, Ph.D. at bkrana@ucsd.edu.
For dietary intake assessment and intervention services, email Cheryl Rock, Ph.D., R.D. at clrock@ucsd.edu and Christine Zoumas, M.S., R.D. at czoumas@ucsd.edu.
For physical activity, fitness, strength, and body composition assessment, email David Wing, M.S. at dwing@eng.ucsd.edu.
|
|
|
-
Hoimes CJ, Flaig TW, Milowsky MI, Friedlander TW, Bilen MA, Gupta S, Srinivas S, Merchan JR, McKay RR (STT), Petrylak DP, Sasse C, Moreno BH, Yu Y, Carret AS, Rosenberg JE. Enfortumab vedotin plus pembrolizumab in previously untreated advanced urothelial cancer. J Clin Oncol. 2023 JAN 01.
-
Cespedes Feliciano EM, Vasan S, Luo J, Binder AM, Chlebowski RT, Quesenberry C, Banack HR, Caan BJ, Paskett ED, Williams GR, Barac A, LaCroix AZ (CCP), Peters U, Reding KW, Pan K, Shadyab AH, Qi L, Anderson GL. Long-term trajectories of physical function decline in women with and without cancer. JAMA Oncol. 2023 JAN 19.
- Lorenz DA, Her HL, Shen KA, Rothamel K, Hutt KR, Nojadera AC, Bruns SC, Manakov SA, Yee BA, Chapman KB, Yeo GW (SFG). Multiplexed transcriptome discovery of RNA-binding protein binding sites by antibody-barcode eCLIP. Nat Methods. 2023 JAN 01.
-
Robinson JT, Thorvaldsdottir H, Turner D, Mesirov JP. igv.js: An embeddable JavaScript implementation of the Integrative Genomics Viewer (IGV). Bioinformatics. 2023 Jan 1
|
|
|
To submit any announcements, funding opportunities, events, or other important items to this newsletter, please make use of the newsletter submission form that is linked below.
Please direct any questions that you may have to our Marketing and Communications Coordinator, Sarah Christie at sjchristie@health.ucsd.edu
|
|
|
|
Want to be highlighted in the MCC weekly newsletter or on the MCC website?
We want to know and share in all of our successes at MCC. To that end, we have created a pipeline for our members to share recent publications, awards, new appointments, and research highlights that you would like to see in our MCC weekly newsletter or on the MCC website. Please provide us with the data that we need to showcase your great work by completing the Member Survey linked below.
We sincerely thank you in advance for your time!
|
|
|
Moores Cancer Center (MCC) is not only one of only 52 National Cancer Institute (NCI)-designated Comprehensive Cancer Centers in the nation, but also the only one providing multidisciplinary, research-driven detection, treatment, survivorship, and prevention of cancer in San Diego County. The 360 MCC member scientists and clinicians hail from 22 UC San Diego specialty departments, Rady Children’s Hospital, San Diego State University, and the La Jolla Institute of Immunology.
With strengths in stem cell research, immune-oncology, precision medicine, cancer disparities, and pre-cancer and cancer-risk research, MCC investigators address translational oncology and drug development through partnerships with biotechnology and pharmaceutical companies. Holding Comprehensive status since 2001, MCC was founded in 1977 by John Mendelsohn and received its NCI designation in 1978.
|
|
|
Department of Research Administration
|
|
|
Manage your preferences | Opt Out using TrueRemove™
Got this as a forward? Sign up to receive our future emails. View this email online.
|
3855 Health Sciences Drive MC 0698 | La Jolla, CA 92093 US
|
|
|
This email was sent to schristie@ucsd.edu.
To continue receiving our emails, add us to your address book.
|
|
|
|